We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Oncogenic protein tyrosine kinases.
- Authors
Saglio, G.; Cilloni, D.
- Abstract
Since it was first recognized, chronic myeloid leukemia (CML) has always represented a unique model to understand the molecular mechanisms underlying the onset and progression of a leukemic process. CML was the first recognized form of cancer to have a strong association with a recurrent chromosomal abnormality, the t(9;22) translocation, which generates the so-called Philadelphia (Ph)-chromosome. Twenty years later, this abnormality was shown to cover a specific molecular defect, a hybridBCR-ABLgene, strongly implicated in the pathogenesis of the disease through the production of a protein with a constitutive tyrosine-kinase activity. Although we still lack a complete definition of all the transformation pathways activated by Bcr-Abl, the recent introduction into clinical practice of tyrosine kinase inhibitor represents a major breakthrough to the management of CML and, furthermore, promises to usher in molecularly targeted therapy for other types of leukemia, lymphoma and cancer.
- Publication
Cellular & Molecular Life Sciences, 2004, Vol 61, Issue 23, p2897
- ISSN
1420-682X
- Publication type
Academic Journal
- DOI
10.1007/s00018-004-4271-0